Antibacterial Resistance Leadership Group 2.0: Back to Business

Henry F. Chambers, Scott R. Evans, Robin Patel, Heather R. Cross, Anthony D. Harris, Yohei Doi, Helen W. Boucher, David Van Duin, Ephraim L. Tsalik, Thomas L. Holland, Melinda M. Pettigrew, Pranita D. Tamma, Kathryn R. Hodges, Maria Souli, Vance G. Fowler

Research output: Contribution to journalReview articlepeer-review

7 Citations (Scopus)


In December 2019, the Antibacterial Resistance Leadership Group (ARLG) was awarded funding for another 7-year cycle to support a clinical research network on antibacterial resistance. ARLG 2.0 has 3 overarching research priorities: infections caused by antibiotic-resistant (AR) gram-negative bacteria, infections caused by AR gram-positive bacteria, and diagnostic tests to optimize use of antibiotics. To support the next generation of AR researchers, the ARLG offers 3 mentoring opportunities: the ARLG Fellowship, Early Stage Investigator seed grants, and the Trialists in Training Program. The purpose of this article is to update the scientific community on the progress made in the original funding period and to encourage submission of clinical research that addresses 1 or more of the research priority areas of ARLG 2.0.

Original languageEnglish
Pages (from-to)730-739
Number of pages10
JournalClinical Infectious Diseases
Issue number4
Publication statusPublished - 15-08-2021

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Infectious Diseases


Dive into the research topics of 'Antibacterial Resistance Leadership Group 2.0: Back to Business'. Together they form a unique fingerprint.

Cite this